Abiopharma

🔍 Lynx1 Capital Management LP (Executive)

Company: Passage BIO, Inc. (PASG)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Acquired 50,055 shares of Common stock, $0.0001 par value per share ("Common Stock") at $4.1175 per share (Direct)
  Date: 2026-06-25 | Code: P | equity_swap_involved: 0 | shares_owned_after: 673,759.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.33 to $4.30 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
• F2: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.